Table 1: Trials Evaluating Memantine for Alzheimer's Disease

Table 1. Trials Evaluating Memantine for Alzheimer's Disease

Trial	Sample Size	Study Population	Treatment	End Points	Results
Winblad and colleagues (1999)¹¹	151	Patients with dementia secondary to AD or vascular dementiaMMSE <10GDS 5-7	Memantine 10 mg daily for 12 weeks	CGI-C and care dependence as reported by the nursing staff	Positive response in CGI-C (p=0.001)Care dependence showed significant improvement with memantine (p=0.016)
Ruther and colleagues (2000)^¹²	531	Patients with advanced dementia secondary to AD, vascular dementia, or a "mixed" form of dementia GDS 5-7	Memantine 15 mg daily for 6 weeks	CGI-C, and ADL-functioning as reported by caregiver via the D-Scale of Change (DS-C)	Memantine showed improvement in 87.3%, 73.1%, and 60% of patients in GDS stages 5, 6, and 7, respectively. In addition, improvements were noted in GDS stages 5, 6, and 7 in all items of the DS-C after 6 weeks (especially the "behaviour" and "ability to communicate" items).
Reisberg and colleagues (2003)^⁶	252	Patients with moderate-to-severe ADMMSE 3-14GDS 5-6	Memantine 10 mg twice daily for 28 weeks	CIBIC-Plus, ADCS-ADLsev, SIB	CIBIC-Plus (p=0.03), ADCS-ADLsev (p=0.003), and SIB (p=0.001) all improved with memantine
Tariot and colleagues (2004)^⁸	403	Patients with moderate-to-severe AD, stable on donepezil therapy for the past 3 monthsMMSE 5-14	Memantine 10 mg twice daily plus donepezil for 24 weeks	Primary:ADCS-ADL, SIB	CIBIC-Plus (p=0.027), ADCS-ADL (p=0.028), and SIB (p=0.001) all improved with memantine/donepezil therapy
ADCS-ADLsev = Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory, ADL = Activities of Daily Living, CGI-C = Clinical Global Impression of Change, CIBIC-Plus = Clinician's Interview-Based Impression of Change Plus Caregiver Input, SIB = Severe Impairment Battery, NPI = Neuropsychiatric Inventory, BGP = Behavioral Rating Scale for Geriatric Patients

Click Here to Return to Article